Anticoagulant reversal

Introduction
Non-vitamin K antagonist oral anticoagulants (NOACs) have emerged as a promising alternative to traditional anticoagulants, however there is one limitation, lack of readily available antidotes. Development of such agents is required to reduce the risk of major bleeding.

Methodology
Species: rats
Rivaroxaban IV injection, applicatio of filter paper soaked with FeCl3 to carotid artery
Timeline: in-life phase 1 day, total 3 weeks

Readouts

• Prothrombin Time (PT)
• Partial Thromboplastin Time (PTT)
• Time to occlusion (TTO)

Application
This elegant model is intended for preclinical efficacy testing of direct anticoagulant antidotes or clotting factor replacement. Option to assess safety of the new drug entity for the risk of thromboembolism is included